Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2021

View Archived Issues

Restored ciliogenesis switches glioma stem cells from self-renewal to differentiation

GSK-852 identified as a soluble BET inhibitor selective for BD2

CHIR-99021 acts as mitochondrial function enhancer and shows activity in models of HD

Medshine Discovery identifies new S1PR1 agonists

Sironax describes new ferroptosis inhibitors

Ennovabio, Shanghai Ennova Biopharmaceutical patent MAP4K1 inhibitors

New CDK12 inhibitors presented by Bayer, Deutsches Krebsforschungszentrum

CD147 as therapeutic target against SARS-CoV-2 and its variants

Model of CDNF gene inactivation points to possible therapies for Parkinson's disease

VBI reports new preclinical data on COVID-19 vaccine candidates VBI-2902, VBI-2905 and VBI-2901

ER-001259851-000, novel selective Axl inhibitor with promising PK profile in vivo

GlaxoSmithKline compounds may illuminate TAF1 (BD2) potential as a therapeutic target

Mindset identifies MSP-4019 and MSP-4020 from Family 4 compounds

BetterLife Pharma reports neurological receptor binding data for TD-0148A

Bioartificial implant delivers anticytokine drugs in response to dynamic biological signals

Vaxil offers update on research and development activities

IDH1 mutations affect antitumor immunity in glioma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...